We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evans Bancorp, Inc. (EVBN) - free report >>
DHI Group, Inc. (DHX) - free report >>
Ionis Pharmaceuticals, Inc. (IONS) - free report >>
Image: Bigstock
New Strong Sell Stocks for February 8th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
AdvanSix Inc. (ASIX - Free Report) is a manufacturer and seller of polymer resins in the United States and around the globe. The Zacks Consensus Estimate for its current year earnings has been revised 3.3% downward over the last 30 days.
Brookfield Business Partners L.P. (BBU - Free Report) is a private equity firm that specializes in acquisition. The Zacks Consensus Estimate for its current year earnings has been revised 0.1% downward over the last 30 days.
DHI Group, Inc. (DHX - Free Report) is a provider of data, insights, and employment connections through specialized services for technology professionals. The Zacks Consensus Estimate for its current year earnings has been revised 15% downward over the last 30 days.
Evans Bancorp, Inc. (EVBN - Free Report) is the financial holding company for Evans Bank, N.A. The Zacks Consensus Estimate for its current year earnings has been revised 6.6% downward over the last 30 days.
Ionis Pharmaceuticals, Inc. (IONS - Free Report) is a discoverer and developer of RNA-targeted therapeutics. The Zacks Consensus Estimate for its current year earnings has been revised 3.8% downward over the last 30 days.
View the entire Zacks Rank #5 List.